AGC Biologics, Inc. – FDA 483, Apr 18, 2025
An FDA inspection of AGC Biologics, Inc. in Bothell, WA, a drug substance manufacturer, revealed significant deficiencies in laboratory data management and critical material inventory. Observations included inadequate review of laboratory data, the ability for analysts to delete electronic raw data, and instrument qualification lacking acceptance criteria. Additionally, the firm's inventory system for working cell banks was found to be inaccurate, with no established procedures for conducting inventory counts.
ID · 5feb9b19-4203-4a42-8153-4c5ad2c4aa43
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.